Previous 10 | Next 10 |
Aduro Biotech (NASDAQ: ADRO ): Q3 GAAP EPS of -$0.26 misses by $0.03 . More news on: Aduro BioTech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
BERKELEY, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of c...
The following slide deck was published by Aduro BioTech, Inc. in conjunction with this Read more ...
Aduro Biotech (NASDAQ: ADRO ) gains on the announcement that two abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting that runs from November 6 to 10. More news on: Aduro BioTech, Inc., Healthcare stocks news, Stocks on the mov...
BERKELEY, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of c...
BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Andrea van Elsas, chief scientific officer of Aduro, is scheduled to present at the 2019 Cantor Global Healthcare Conference in New York, New York on Friday, October 4, 2019 at 8:55 ...
BERKELEY, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of ...
BERKELEY, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the H.C. Wainwright 21 st Annual Global Investment Conference in New York, Ne...
Aduro Biotech (NASDAQ: ADRO ): Q2 GAAP EPS of -$0.23 beats by $0.04 . More news on: Aduro BioTech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
BERKELEY, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of c...
News, Short Squeeze, Breakout and More Instantly...
Aduro Biotech Inc. Company Name:
ADRO Stock Symbol:
NASDAQ Market:
The 15th Annual Global CSR & ESG Awards Honours 2023 Winners DA NANG, VIETNAM, Aug 30, 2023 - (ACN Newswire) - The 15th Annual Global CSR & ESG Summit & Awards ended on a high note before a full house in Da Nang, Vietnam, on August 28. Organized at the Novotel Danang Pre...
Combined Company Will H ave Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Chinook Therap...
One-for-Five Reverse Stock Split to be Effective October 2, 2020 BERKELEY, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADURO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (ST...